The present invention relates to the field of wood rosin and resin acid derivatives and more particularly to abietane-type diterpenoids as well as different uses thereof. Furthermore, the present invention relates to methods of coating surfaces, preventing, reducing or inhibiting bacterial biofilm formation, and treating or preventing disorders caused by microbial growth and viability as well as bacterial colonization.

The present invention relates to the field of wood rosin and resin acid derivatives and more particularly to abietane-type diterpenoids as well as different uses thereof. Furthermore, the present invention relates to methods of coating surfaces, preventing, reducing or inhibiting bacterial biofilm formation, and treating or preventing disorders caused by microbial growth and viability as well as bacterial colonization.

The present invention relates to compounds of formula (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R.sup.1a, R.sup.2b, R.sup.2c, R.sup.5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

A process method for producing a pesticide by using carbon dioxide includes: weighing a 1,3-cyclohexanedione substrate 1(a-e), a catalyst and Cs.sub.2CO.sub.3 in a Schlenk bottle, degassing, and continuously introducing 1 atm of carbon dioxide; adding a solvent and reacting for 48 h in an oil bath at 50° C. After the reaction was completed, post-treatment was carried out to obtain a 2-carboxyl-1,3-cyclohexanedione compound 2(a-e). The obtained acid is acylated and then added dropwise to a dichloromethane solution containing aniline to react for 2 h at room temperature. After the reaction, column chromatography was performed to obtain a pesticide compound 3(a-e). Adding the pesticide compound 3(a-e) into 50% concentrated sulfuric acid and refluxing at 80° C. for 8 hours. Through separation, a pesticide product compound 4(a-e) was obtained. The process method is simple, with low requirements on equipment, wide sources of raw materials, low cost, low toxicity and easy industrial scale-up production.

A process method for producing a pesticide by using carbon dioxide includes: weighing a 1,3-cyclohexanedione substrate 1(a-e), a catalyst and Cs.sub.2CO.sub.3 in a Schlenk bottle, degassing, and continuously introducing 1 atm of carbon dioxide; adding a solvent and reacting for 48 h in an oil bath at 50° C. After the reaction was completed, post-treatment was carried out to obtain a 2-carboxyl-1,3-cyclohexanedione compound 2(a-e). The obtained acid is acylated and then added dropwise to a dichloromethane solution containing aniline to react for 2 h at room temperature. After the reaction, column chromatography was performed to obtain a pesticide compound 3(a-e). Adding the pesticide compound 3(a-e) into 50% concentrated sulfuric acid and refluxing at 80° C. for 8 hours. Through separation, a pesticide product compound 4(a-e) was obtained. The process method is simple, with low requirements on equipment, wide sources of raw materials, low cost, low toxicity and easy industrial scale-up production.

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.